ESMO 2017

Sep 08, 2017

The Epic Sciences team attended and presented data at the European Society of Medical Oncology (ESMO) in Madrid, Spain from September 8th – 12th, 2017.

We presented the below data at ESMO 2017:

Phase 1 Study of the PSMA-Targeted Small-Molecule Drug Conjugate EC1169 in Patients with Metastatic Castrate-Resistant Prostate Cancer (mCRPC)

Phenotypic Circulating Tumor Cell (CTC) Classifier of Genomic Instability (GI) Associates with Improved Overall Survival (OS) for Metastatic Castration-Resistant Prostate Cancer (mCRPC) Patients (pts) Receiving Platinum Agents in Addition to Taxanes.

‍